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James R. EdgarAbstract
Exosomes are extracellular vesicles first described as
such 30 years ago and since implicated in cell–cell
communication and the transmission of disease states,
and explored as a means of drug discovery. Yet
fundamental questions about their biology remain
unanswered. Here I explore what exosomes are,
highlight the difficulties in studying them and explain
the current definition and some of the outstanding
issues in exosome biology.of cellular waste disposal. It is only in the past decadeWhat is the current definition of an exosome?
That is a very good question. Since the original descrip-
tion of exosomes over 30 years ago, the term has been
loosely used for various forms of extracellular vesicle,
muddying the field and contributing to the scepticism
with which the research has sometimes been met. Exo-
somes are best defined as extracellular vesicles that are
released from cells upon fusion of an intermediate endo-
cytic compartment, the multivesicular body (MVB), with
the plasma membrane. This liberates intraluminal vesi-
cles (ILVs) into the extracellular milieu and the vesicles
thereby released are what we know as exosomes (Fig. 1).
There are other types of microvesicle, including apop-
totic bodies and ectosomes, which are derived from cells
undergoing apoptosis and plasma membrane shedding,
respectively. Although apoptotic bodies, ectosomes and
exosomes are all roughly the same size (typically 40–
100 nm) and all also contain ‘gulps’ of cytosol, they are
different species of vesicles and understanding differ-
ences between them is of paramount importance but has
too often been overlooked.
How were exosomes first recognized as distinct
entities?
The presence of membranous vesicles outside cells was
first recognized 50 years ago, although these were origin-
ally assumed to be waste products released via sheddingCorrespondence: je333@cam.ac.uk
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now call exosomes didn’t come until 1983, from studies
on the loss of transferrin during the maturation of
reticulocytes into erythrocytes [1]. These studies showed,
by following transferrin-gold conjugates through the
endocytic system, that ILVs generated in MVBs can be
released to the extracellular space through fusion with
the plasma membrane [2], although it was not until
1987 that the term ‘exosome’ was coined for them [3].
Even then, however, these extracellular vesicles were
largely ignored, forgotten or, again, dismissed as a means
that interest in exosomes has exploded, with a nearly
tenfold increase in publications in as many years (115 in
2006, 1010 in 2015).Why this explosion of interest?
For at least three reasons. First, they are thought to pro-
vide a means of intercellular communication and of
transmission of macromolecules between cells. Second,
in the past decade, exosomes have been attributed roles
in the spread of proteins, lipids, mRNA, miRNA and
DNA and as contributing factors in the development of
several diseases. And third, they have been proposed to
be useful vectors for drugs because they are composed
of cell membranes, rather than synthetic polymers, and
as such are better tolerated by the host. In fact, some of
the earliest exosome research indicated that they can
carry the MHC–peptide complexes that are recognized
by T lymphocytes [4] and that secretion of such exo-
somes could promote antitumour immune responses in
mice in vivo [5]. Exosome therapies are now being ex-
plored in anti-cancer clinical trials and recent reports
claim taxol-filled exosomes can be used to treat cancers
in mice at 50-fold lower doses than conventional treat-
ments, with the additional benefit that exosomes do not
invoke an immune response [6].
Yet despite 20 years of research, the very basics of exo-
some biology are in their infancy and we know little of
the part they play in normal cellular physiology.tributed under the terms of the Creative Commons Attribution 4.0 International
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Fig. 1. Exosomes correspond to intraluminal vesicles of
multivesicular bodies. A transmission electron micrograph of an
Epstein–Barr virus-transformed B cell displaying newly expelled
exosomes at the plasma membrane. Multivesicular bodies (MVB) can
be seen which can deliver content to lysosomes for degradation or
can fuse with the cell surface to release intraluminal vesicles as
exosomes, indicated by the arrows at the top of the picture
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Yes and no. We do know that they are made as ILVs;
but first of all, not all ILVs finish up as exosomes, and
second, the mechanism of their generation in endosomes
is not fully understood. Most conventional membrane
budding processes deform membrane from an organelle
into the cytoplasm but in ILV formation the membrane
buds away from the cytoplasm and into the endosome.
This unconventional budding process is not limited to
ILV generation but also takes place during enveloped
virus budding from the cytosol and during cytokinesis
[7], and it requires specialised machinery.
ILVs (and thus exosomes) can be generated at the
endosomal limiting membrane by at least two mecha-
nisms, one of which depends on the ESCRT machinery
(ESCRT stands for endosomal sorting complexes re-
quired for transport) whereas the other is ESCRT-
independent (Fig. 2).
The ESCRT machinery consists of a set of cytosolic
protein complexes that are recruited to endosomes by
membrane proteins that have been tagged, usually with
ubiquitin on their cytosolic domains. The ubiquitin tag
is recognized by the first of the ESCRT complexes,
ESCRT-0, which is thus recruited to the endosomal
membrane and passes ubiquitinated cargos to ESCRT-I,
one of whose components, Tsg101, also recognizes ubi-
quitin. The recruitment of the ESCRT machinery acts to
both cluster the ubiquitinated cargo proteins on theendosome and induce curvature of the endosomal mem-
brane to form ILVs.
But ILVs are still able to form in the absence of
ESCRTs [8], so other means of generating ILVs must
exist, although the mechanisms for their generation are
less clear. Generation of these ESCRT-independent ILVs
requires the tetraspanin CD63—a protein abundant on
ILVs but with unclear function [9]—and may be facili-
tated by cone-shaped bending properties of lipids such
as ceramide [10].If not all ILVs become exosomes, what determines
the fate of an ILV?
The destiny of ILVs is directed by the fate of the MVB
they reside in. Confusingly, in addition to different types
of ILVs, there are also different types of MVBs [11] and
what regulates the fate of these endosomes is another in-
teresting question. MVBs have several potential fates
(Fig. 2) and can either fuse with lysosomes (where con-
tents are degraded and recycled), fuse with the plasma
membrane (where ILVs are released as exosomes), as I
have already mentioned, or contribute to the generation
of specialised organelles, such as melanosomes (in mela-
nocytes), Weibel-Palade bodies (endothelial cells), azuro-
philic granules (in neutrophils) and secretory granules
(in mast cells). The levels of cholesterol on MVBs appear
to play a part in regulating their fate, cholesterol-rich
MVBs being directed to the plasma membrane for exo-
some release, while cholesterol-poor MVBs are targeted
to the lysosome [12].
But what regulates the balance between exosome re-
lease and alternative fates of ILVs remains engimatic.What about differences between cells: do all cells
release exosomes?
Well, not all cells have an endomembrane system, so no.
But most mammalian cells contain endomembranes and
generate ILVs within MVBs, though remarkably little is
known about exosome release in most cell types.
Some cells—for example, the B cells, dendritic cells
and mast cells of the immune system—appear to release
exosomes constitutively; in fact, most of the data we
have on exosomes comes from immune cells. As well as
releasing exosomes constitutively, these cells may also
be stimulated to secrete exosomes by cellular interac-
tions. For example, murine dendritic cells, which are
specialized to activate T lymphocytes, secrete higher
levels of exosomes upon interaction with antigen-
specific CD4+ T lymphocytes [13]. In fact, lymphocyte
interactions generally can be accompanied by exosome
release; human T cells (including primary T cells from
blood, T cell clones and Jurkat cell lines) release exo-
somes upon activation of their antigen receptors [14]
Fig. 2. ILVs are generated by invagination of the endosomal membrane and have three possible fates. Inset: intraluminal vesicles (ILV) are formed
by invagination of the endosomal membrane by either ESCRT-dependent or ESCRT-independent mechanisms. Matured endosomes accumulate
ILVs within their lumen and have three distinct fates. They may deliver content that contributes to the biogenesis of specialized lysosome-related
organelles (for example, melanosomes, Weibel-Palade bodies, azurophilic granules), they may fuse with lysosomes or they may fuse with the
plasma membrane where released ILVs are now termed ‘exosomes’
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with antigen-specific CD4+ T cells [15].
Other cell types can be pushed to secrete exosomes by
means of calcium ionophores or other stimuli [16, 17],
but the extent of physiological exosome secretion in
non-immune cells is largely unknown.
What happens when exosomes reach an acceptor
cell?
We don’t know exactly. Exosomes that transfer mem-
brane proteins or luminal content to the acceptor cell
may be engulfed whole or the exosome membrane may
fuse directly with the host plasma membrane (Fig. 3).
Alternatively, exosomes may not need to be taken up by
cells to elicit a physiological response: follicular dendritic
cells, for example, carry on their cell surface exosomes
that bear MHC–peptide complexes and other proteins
that they do not express and are thereby enabled to acti-
vate immune cells with which they interact [18].For intercellular transmission, various mechanisms of
phagocytosis and endocytosis of extracellular vesicles
have been described and which mechanism operates
may depend upon vesicle size, which may in turn de-
pend upon the cargo carried by the vesicle. In order for
material to be released to an acceptor cell, exosomes
must fuse with the host cell and this takes place via ei-
ther direct fusion with the plasma membrane or a ‘back-
fusion’ step from within a host endocytic organelle after
the exosome has been engulfed. The process of back-
fusion is not entirely clear, although it appears to require
the unconventional lipid LBPA and protein Alix [19]
(and is exploited by anthrax toxin lethal factor to escape
from endosomes to the cytosol [20]).
Whether exosomes fuse with target cells or act via in-
teractions with cell-surface proteins, or both, is another
fundamental cell biology question that will need to be
addressed if we are to understand the functions of
exosomes.
Fig. 3. Exosome uptake by recipient cells. Fusion of MVBs with the cell surface releases ILVs as exosomes. In order for exosomes to elicit a
response from recipient cells they might either fuse with plasma membrane (a) or be taken up whole via endocytosis (b), following which the
exosome must be delivered to the cytosol, for example, via a back-fusion event (c). Alternatively, exosomes may attach to the surface of recipient
cells to elicit a signalling response (d)
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information transfer? What biological functions
have been established for exosomes?
There are many proposed functions for exosomes, the
best-established being in immune responses. Exosomes
isolated from B lymphocytes and bearing MHC class II
molecules were shown in early experiments [4] to activate
T lymphocytes in vitro, suggesting that they were commu-
nicating with the T lymphocytes in just the way that the
parent B cells did. I have already mentioned later work by
the same group, who showed that exosomes derived from
dendritic cells, which are specialized to activate T cells in
the initiation of immune responses, could promote antitu-
mour immune responses in mice [5], exciting interest in
the possibility of practical applications.
Or, as with follicular dendritic cells, exosome-associated
MHC II can be found on the surface of cell types that nei-
ther express MHC II nor secrete exosomes, indicating that
exosomes are delivered from one cell type to another [18].
However, exosomes may have roles other than in im-
mune responses as several non-immune cells secrete
exosomes. The only physiological role so far reported for
non-immune cells is in keratinocyte-derived exosomes,
which have been shown to modulate melanin synthesis
by increasing the expression and activity of proteinswithin the melanosomes that modulate skin pigmenta-
tion [21].
How exactly would exosomes from one cell
influence the expression and activity of proteins
in an acceptor cell?
Exosomes transfer not only protein and lipids but
mRNA and microRNA into acceptor cells and these
RNAs have been shown in experiments in vitro to have
functional effects in recipient cells. For example, exo-
somes from mice can be transferred to human cells and
mRNA can be translated into mouse protein [22]. Simi-
larly, microRNAs—double-stranded RNA fragments that
can regulate specific sets of mRNA (and so protein
levels)—can act functionally in acceptor cells. The mode
of action of exosomes has been a focus of special interest
in cancer biology. Exosomes from breast cancer cell
lines, for example, have been shown to be enriched for
miRNAs relative to nontumorigenic breast cell lines and
exposure of normal cells to exosomes derived from
breast cancer cell lines increased both cell survival and
proliferation, accompanied by loss of expression of some
tumour-suppressor proteins [23]. Exosome levels are ele-
vated in the serum of some cancer patients versus con-
trols. However, whether these vesicles are exosomes or
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unclear—I have already mentioned this persistent problem
in exosome research.
So exosomes can also contribute to disease?
Yes indeed. As exosomes provide a means of intercellular
communication, they may also act as vehicles for ‘bad’ com-
munication or spread. As well as miRNAs in the case of
cancer, exosomes have been shown to contain numerous
disease-associated cargos—for example, neurodegenerative-
associated peptides, such as Aβ [24] (in Alzheimer’s
disease), tau [25] (in numerous neurodegenerative diseases),
prions [26] (in transmissible spongiform encephalopathies),
alpha-synuclein [27] (in synucleinopathies, including
Parkinson’s disease) and superoxide dismutase 1 [28] (in
amyotrophic lateral sclerosis). Exosomes have thus been
suggested to be propagators of neurodegenerative protein
spread, although some cargos are easier to envisage than
others.
Of the neurodegenerative-associated proteins, only
some are integral membrane proteins, that is, proteins
inserted into lipid bilayers, rather than cytosolic. Sorting
of proteins into ILVs (and thus exosomes) is easier to en-
visage for membrane proteins, where tags such as ubi-
quitin regulate where they end up. So far, the presence
of both Aβ [29] and PrPc [26] has in fact been shown in
ILVs, though this has not been demonstrated for other
membrane proteins, such as alpha-synuclein and tau.
The mechanism whereby cytosolic proteins may be
sorted to ILVs/exosomes, however, is not clear. In order
for cytosolic proteins to become concentrated in ILVs,
they would require positive incorporation and sorting,
possibly by membrane-associated components on endo-
somes. All we can say is that there is evidence that this
does in fact happen; cytosolic factors such as miRNAs
are enriched in exosomes relative to cytosol, indicating
that sorting must occur whereby certain miRNAs are
concentrated and others are not [30].
The means by which disease-associated factors spread
between cells remains poorly understood and exosomes
would provide a means for such transmission. The pres-
ence of exosomal proteins, such as Alix, in association
with Alzheimer’s senile plaques strengthens the circum-
stantial case for exosomes as a mediator in such spread.
The hope is that having a means to regulate exosome re-
lease and spread may be useful in combatting some of
these diseases but much more basic biology needs to be
established before then.
Now I’m confused—what determines what
exosomes contain?
Exosomes will contain whatever is sorted into them dur-
ing their formation (as ILVs). For membrane proteins,
this usually occurs through ubiquitination, which acts asa substrate for recruitment of the ESCRT machinery and
subsequent generation of ESCRT-dependent ILVs.
The mechanisms that concentrate cytosolic factors are
currently unknown. Although it seems clear that miR-
NAs, for example, are enriched relative to the amount in
their parent cells, and are not randomly incorporated
into exosomes, it is not clear how some are enriched
more than others. There are currently a few hypotheses
for miRNA sorting, including sorting via sumoylated
heterogeneous nuclear ribonucleoproteins [31] or by a
miRNA-induced silencing complex (miRISC) [32].
Because of the difficulties in separating exosomes from
other extracellular vesicles, it is likely that some cargos
reported to be enriched in ‘exosomes’ may in fact be
contained in contaminant vesicles that are not exo-
somes. While many researchers are very stringent about
applying the labels ‘exosomes’ and ‘extracellular vesicles’
correctly, others unfortunately are not. In addition, as I
have said before, cytosolic proteins are likely to be found
in exosome preparations because the exosome lumen is
made of cytosol.
So how exactly can you be sure that a given
extracellular vesicle is an exosome and not
something else?
This is an interesting question that has a complex an-
swer. Ideally, an intracellular compartment is identified
by a specific biological marker, as, for example, in the
case of the Golgi, nucleus or mitochondria, all of which
carry proteins not found, or found at much lower levels,
elsewhere.
One problem is that ILVs, and thus exosomes, represent
an intermediate compartment of an intermediate. MVBs
are not static organelles but rather undergo continuous
maturation, in the course of which they gain and lose pro-
teins. There will never be an exclusive marker for exo-
somes because any cargo on the ILV/exosome membrane
must first be on the limiting membrane of the endosome
and anything found inside must first come from the cyto-
sol. A cargo may be concentrated on ILVs/exosomes but it
will also be elsewhere. CD63 could be thought of as a
pseudo-marker for exosomes. ILVs and exosomes are
enriched in several such tetraspanins and my colleagues
and I have show that CD63 is required for ESCRT-
independent ILV formation [9]. Alix also appears to be
concentrated in ILVs/exosomes [33], as does Tsg101, a
component of ESCRT-I, which has been used as a marker
of exosomes in numerous studies [33, 34], although the
presence of Tsg101 in ILVs or exosomes does not fit with
conventional models of ILV formation. Although Tsg101
is involved in ESCRT-dependent ILV formation, as men-
tioned earlier, it, along with other ESCRT components,
should disassociate from the endosomal membrane prior
to an ILV pinching off the endosomal membrane to allow
Edgar BMC Biology  (2016) 14:46 Page 6 of 7it to participate in further events [35]. Exactly when
ESCRT-I components ‘fall off ’ the membrane is unknown
but it is conventionally thought to be prior to ILV forma-
tion, so Tsg101 should remain cytosolic and available for
subsequent rounds of ILV formation. It is possible that
some Tsg101 may be ‘swallowed’ into the forming ILV
lumen, but levels should be negligible.
So are you saying there is no reliable marker for
endosomes?
There may not be—not a single reliable one. Ultimately,
perhaps the best method of defining exosomes biochem-
ically may be through a combination of markers, includ-
ing tetraspanins, Alix and others, with a concomitant
exclusion of resident plasma membrane proteins. Al-
though ILVs/exosomes will by their nature contain some
plasma membrane proteins and the plasma membrane
will contain some ILV/exosomal proteins, it should be
possible to define relative levels and/or enrichment of
proteins of exosomes that distinguish them from other
microvesicles. Cargos such as MHC II from B cells and
other cell type-specific antigens may also help to distin-
guish exosomes from other forms of extracellular vesicle.
Common exosomal cargos include tetraspanins (CD63,
CD81, CD9), antigen presentation molecules (MHC I
and MHC II) and others (Alix, flotillin-1). An online
database exists [36] where proteins, lipids and RNA are
catalogued from published and unpublished exosomal
studies.
If they are so hard to characterize reliably, how
are exosomes isolated and studied?
Exosomes are rarely imaged by conventional methods as
they are too small to be resolved by fluorescence micros-
copy and their release may be a rare event. A few studies
have imaged exosome release occurring in cell cultures
by various electron microscopic techniques but, more
commonly, exosomes are pooled from cellular super-
natant or animal fluids. Traditionally, they have been
isolated by differential centrifugation from culture
medium whereby larger contaminants are first excluded
by pelleting out through increasing speeds of centrifuga-
tion before exosomes, small extracellular vesicles and
even protein aggregates are pelleted at very high speeds
(~100,000 × g) [37]. These preparations therefore repre-
sent an enrichment rather than a purification. Enriched
preparations are commonly analysed by biochemistry,
mass spectrometry or electron microscopy. Electron mi-
croscopy of isolated fractions as ‘whole mounts’ make it
possible to immuno-label vesicles, with the limitation
that isolated preparations do not provide the same in-
ternal controls as labelling sections of cells. Remarkably
little attention has been paid to the characterization of
exosomes, although efforts are being made to repair thisomission with guidelines and criteria for defining groups
of extracellular vesicles [38].
What would you say are the most important
issues in exosome research?
Without doubt the single most important issue is actu-
ally understanding the biological significance of these
structures. With so little known about their basic
physiological functions, it may seem hard to understand
how exosomes have been implicated in the pathogenesis
of so many disparate disease states. Fundamental ques-
tions remain about exosome generation, fate and normal
function but, ultimately, in order to understand exo-
somes, one must first understand ILVs, a fact that is too
often overlooked. Meanwhile, it is important that publi-
cations on exosomes give a careful and explicit account
of the criteria used for distinguishing them from other
extracellular vesicles to avoid confusing the field and en-
couraging scepticism.
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